Refractory cancers biospecimen acquisition and genomic characterization
Ended Awarded Last action
- Contract number
- 75N91018F00072
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,289,078
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $4,289,078.05 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$1,106 | |
| Other Administrative Action | $40,271 | |
| Exercise an Option | $258,637 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $3,991,276 |
Show all 12
About this award
The National Cancer Institute issued a delivery order to Leidos Biomedical Research Inc. on September 24, 2018, with a ceiling value of $4.289 million for refractory cancers biospecimen acquisition and genomic characterization under a cost-plus-fixed-fee structure. Ultimate completion date is March 31, 2025.
Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) subsidiary of Leidos Holdings, Inc., serving as the NCI's primary biomedical research contractor. Place of performance is Frederick, MD.
Service Contract Inventory data shows the order invoiced $3.4 million in FY2023 with 1.0 FTE and 1,987 contractor hours at a derived rate of $1,726.22 per hour. FY2024 activity dropped to $23 thousand invoiced, 0.1 FTE, and 220 contractor hours at $103.87 per hour, with no subcontractors reported. The contract has been self-performed by the prime throughout its reported fiscal years.
Quick answers
Who was awarded contract 75N91018F00072?
75N91018F00072 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 24, 2018.
How much is contract 75N91018F00072 worth?
The government has obligated $4,289,078 on 75N91018F00072.
Is contract 75N91018F00072 an order under another contract?
Yes. 75N91018F00072 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract 75N91018F00072 competed?
The extent of competition for 75N91018F00072 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award